Recro Pharma Inc. (REPH) 7.94 $REPH Recro Pharma to

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 10:19 PM

Recro Pharma Inc. (REPH) 7.94 $REPH

Recro Pharma to Present at the Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings that is currently developing non-opioid products for the treatment of serious acute pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference on Thursday, June 9, 2016 at 11:00 am EDT. The conference is being held at the Grand Hyatt in New York City.
REPH: 7.94 (+0.02)

Recro Pharma reports 1Q loss
Automated Insights - Thu May 12, 8:16AM CDT
MALVERN, Pa. (AP) _ Recro Pharma Inc. (REPH) on Thursday reported a loss of $6.5 million in its first quarter.
REPH: 7.94 (+0.02)

Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting
GlobeNewswire - Thu May 12, 8:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing non-opioid products for the treatment of serious acute pain, today announced a poster presentation at the American Pain Society's 35 Annual Scientific Meeting, taking place May 11-14, 2016, in Austin, TX. The poster presentation highlights data from a clinical trial evaluating the efficacy and safety of intravenous (IV) meloxicam (N1539), in subjects with moderate to severe pain following open abdominal hysterectomy.
REPH: 7.94 (+0.02)

Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 4.10 (-0.09), REPH: 7.94 (+0.02)

Recro Pharma Reports Year End 2015 Financial Results
GlobeNewswire - Thu Mar 24, 7:20AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of serious acute pain, today reported financial results for the year ended December 31, 2015.
REPH: 7.94 (+0.02)

Recro Pharma to Present at the 28th Annual ROTH Conference
GlobeNewswire - Mon Mar 07, 7:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 28 Annual ROTH Conference on Monday, March 14, 2016 at 5:30 pm PST. The conference is being held at the Ritz Carlton Hotel in Dana Point, CA.
REPH: 7.94 (+0.02)

Recro Pharma to Present at NobleCon12 Investor Conference
GlobeNewswire - Thu Jan 14, 12:19PM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at Noble Financial Capital Markets' 12th Annual Investor Conference (NobleCon12) on Tuesday, January 19, 2016 at 4:00 pm EST. The conference is being held at Club Med in Sandpiper Bay, Florida.
REPH: 7.94 (+0.02)

Global Acute Pain Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/k9flzp/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Pain Overview - Therapeutics Development - Pipeline Products for Acute Pain - Overview - Pipeline Products for Acute Pain - Comparative Analysis - Acute Pain - Therapeutics under Development by Companies - Acute Pain - Therapeutics under Investigation by Universities/Institutes - Acute Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Pain - Products under Development by Companies - Acute Pain - Products under Investigation by Universities/Institutes - Acute Pain - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - Amorsa Therapeutics Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - AskAt Inc. - Cara Therapeutics, Inc. - Centrexion Corporation - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Dompe Farmaceutici S.p.A. - Grunenthal GmbH - INSYS Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt Plc - MEDRx Co., Ltd. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Orexo AB - Orion Oyj - Pacira Pharmaceuticals, Inc. - Phosphagenics Limited - Recro Pharma, Inc. - Shulov Innovative Science Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. For more information visit http://www.researchandmarkets.com/research/k9flzp/acute_pain
ACRX: 2.73 (+0.01), KMPH: 4.40 (+0.15), NKTR: 15.54 (+0.45), INSY: 13.07 (+0.29), AVXL: 4.27 (+0.12), PCRX: 39.99 (+2.06), REPH: 7.94 (+0.02), PTIE: 2.07 (+0.02)

The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Amazon.com, Energy Focus and NVIDIA
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Amazon.com, Energy Focus and NVIDIA
AMZN: 722.08 (+11.48), EFOI: 6.10 (+0.18), EGRX: 39.40 (+1.10), REPH: 7.94 (+0.02), NVDA: 48.49 (+1.26)

Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam
GlobeNewswire - Wed Jan 06, 6:00AM CST
IV Meloxicam Well Tolerated with Statistically Significant Analgesic Effect Reported
REPH: 7.94 (+0.02)

Buffett Fans Take Note: 5 Stocks That Crushed Berkshire Hathaway in 2015
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:23PM CST
There is no doubt that Berkshire Hathaway Inc. (BRK. is a stock that most investors want in their portfolio.
AMZN: 722.08 (+11.48), EFOI: 6.10 (+0.18), AXP: 63.25 (+1.30), IBM: 155.35 (+2.43), EGRX: 39.40 (+1.10), BRK.B: 145.98 (+2.04), REPH: 7.94 (+0.02), NVDA: 48.49 (+1.26)

5 Small Cap ETFs & Stocks that Beat Russell 2000 in 2015
Sweta Killa - Zacks Investment Research - Mon Jan 04, 9:59AM CST
These ETFs and stocks have shown strong resilience to the sharp downturn in the small cap space and the trend is likely to continue, making these lucrative picks for 2016.
PSCH: 70.70 (+1.33), NPTN: 9.81 (+0.62), LPTH: 1.72 (-0.04), REPH: 7.94 (+0.02), PSCT: 57.22 (+0.83), PSCU: 47.98 (+0.63)

The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Energy Focus, Hanwha Q CELLS and LightPath Technologies
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:30AM CST
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Energy Focus, Hanwha Q CELLS and LightPath Technologies
EFOI: 6.10 (+0.18), LPTH: 1.72 (-0.04), EGRX: 39.40 (+1.10), REPH: 7.94 (+0.02), HQCL: 14.63 (+0.68)

Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer
GlobeNewswire - Wed Dec 02, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced the appointment of Stewart McCallum, M.D., as Chief Medical Officer.
REPH: 7.94 (+0.02)

Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 24, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 2015 Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 9:10 am EST. The conference is being held at the Lotte New York Palace Hotel in New York City.
REPH: 7.94 (+0.02)

Recro Pharma Reports Third Quarter 2015 Financial Results
GlobeNewswire - Fri Nov 13, 5:59AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today reported financial results for the third quarter ended September 30, 2015.
REPH: 7.94 (+0.02)

Recro Pharma to Participate in Upcoming Investor Conferences
GlobeNewswire - Thu Nov 12, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will participate in the following upcoming investor conferences:
REPH: 7.94 (+0.02)

Recro Pharma Provides Pipeline Update
GlobeNewswire - Mon Oct 26, 7:00AM CDT
IV Meloxicam Advancing to Phase III; Pivotal Trials Expected to Commence in First Quarter 2016
REPH: 7.94 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CashorTrade and Front Gate Unite for Ticket Resale

Big News for Festival Enthusiasts Imagine the scene: you've snagged tickets to the hottest festival of the year—maybe Lollapalooza or Austin City Limits—but life throws a curveball, and you can't go. That's where CashorTrade and Front Gate Tickets come in, forming a dynamic duo for festival-goers who need to swap tickets at face value. It’s like a lifeline for every...

Apollo Scooters Reveal the Truth About Winter Range Loss

When the mercury dips, how far can your electric scooter really take you? Apollo Scooters has put some meat on the bones of this question, digging through over half a million rides to bust the myth that chillier days chop your scooter's range by half. Reality Check on Winter Range Loss For years, folks have griped that cold weather slashes electric vehicle range by a...

Legacy of Professor Raymond Yukna: A Laser Pioneer

End of an Era in Periodontology For those of us who have a stake in the world of dental technology, today hangs heavy. We talk about innovators, pioneers, and game-changers all the time, but Dr. Raymond A. Yukna wasn't just another name on that list - he was the list. The guy practically wrote the book on modern periodontal therapy. With his passing, we're not just saying...

Blue Moon Metals Scraps Major Acquisition Plan

Blue Moon Metals' Acquisition Detour Blue Moon Metals Inc. (NASDAQ: BMM), a name that's been stirring up chatter for its ambitious mining ventures, has waved goodbye to its planned acquisition of 33 U.S.-based tungsten and antimony projects. This move, announced on October 30, 2026, may have caught some investors off guard. The acquisition sounded like a good fit: a...

Co-op Giants Earn $309B: Key Players Spotlighted

Co-ops Punch Above Their Weight Forget the tired stereotypes about co-ops as small-time players. The NCB Co-op 100® Report lands like a punch with a staggering revelation: $309 billion in revenue for 2025. That's no small potatoes, and it shows these cooperatives, sprinkled across agriculture, finance, and beyond, are no shy creatures—they're major contenders in...

Reynolds Launches Holiday-Themed Snowflakes Foil

Festive Foil for Holiday Creativity Well, just like that, Reynolds Wrap® is sprinkling some holiday magic into kitchens across the country. They're rolling out this limited-edition Snowflakes Fun Foil®, and it's not just aluminum with a pretty design—it's a tool for all those holiday-driven projects and gatherings. It's that time of year when the air hums with the...

Gildan Investors on Edge Amid Allegations and Lawsuit

Another Market Flash: Gildan Enters Rough Waters New Orleans has put a spotlight on Gildan Activewear, and not in a flattering way. We're talking about that precarious position corporations sometimes find themselves in when their dirty laundry gets aired out for the public to scrutinize. ClaimsFiler, the service urging shareholders to come forward, reminds folks that the...

Gastops and Bell: A New Era in Aerospace Collaboration

Gastops and Bell Seal a Forward-Looking Deal Who would've thought Gastops and Bell, two juggernauts in their respective fields, would link arms to drive the aerospace game forward in Canada? That's right, a Memorandum of Understanding (MOU) was inked between these titans at the 2026 Canadian Aerospace Summit, paving the way for collaboration on future programs. This isn't...

Pudu Robotics Eyes Robust Growth from New German HQ

Pudu Robotics Solidifies European Expansion with New HQ There's a new sheriff in Neuss, Germany, and it's not wearing a cowboy hat—it's stocked with commercial robots. Yep, Pudu Robotics is planting its flag right there, aiming to supercharge its already rapid growth across Europe. From Store Floors to Hospital Halls Pudu's got some serious momentum. We're talking a...

Transforming Healthcare Leadership Through Systemic Change

Reframing Physician Leadership for Systemic Transformation Here we go, diving into some serious change-making in the healthcare sphere. If you've ever wandered through a hospital corridor, you've likely felt the tension between docs and the suits. The American Association for Physician Leadership (AAPL) is stirring the pot with a fresh book that might just be the catalyst...